Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | IL3 |
| Gene Name: | IL3 |
| Protein Full Name: | Interleukin-3 |
| Alias: | Hematopoietic growth factor;Mast cell growth factor;Multipotential colony-stimulating factor;P-cell-stimulating factor |
| Mass (Da): | 17233 |
| Number AA: | 152 |
| UniProt ID: | P08700 |
| Locus ID: | 3562 |
| COSMIC ID: | IL3 |
| Gene location on chromosome: | 5q31 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.24 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | t(5;14)(q31;q32) translocation in B-cell acute lymphoblastic leukemia (change to immunoglobulin gene promoter control) |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | IL3 is a cytokine and a colony stimulating factor that plays hematopoietic roles by promoting the production, differentiation, and function of granulocytes and monocytes/macrophages. It may also induce the self-renewal of pluripotent hematopoietic stem cells. Activation of its associated receptor, IL3R, activates the JAK2/STAT5 pathway and induces c-myc and ras for cell-cycle progression and suppression of apoptosis, respectively. Overexpression of IL3 has been implicated in B-cell acute lymphoblastic leukemia. A t(5;14)(q31:q32) mutation breaks the promoter region of IL3 and causes the immunoglobulin gene promoter to control IL3 expression. |